Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors

Molecular Cancer Therapeutics

Volumn 13, Issue 4, 2014, Pages 986-995

  Thurber, Greg M ^c   Reiner, Thomas ^d   Yang, Katherine S ^a   Kohler, Rainer H ^a   Weissleder, Ralph ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BODIPY 650 665 SUCCINIMIDYL ESTER; BODIPY FL; DYE; ESTER DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLAPARIB; UNCLASSIFIED DRUG; ENZYME INHIBITOR; MOLECULAR LIBRARY; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW VELOCITY; BLOOD VESSEL PERMEABILITY; CELL CULTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG SYNTHESIS; DRUG UPTAKE; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; IC 50; LIPOPHILICITY; MATHEMATICAL MODEL; MEMBRANE PERMEABILITY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; CELL FRACTIONATION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; EXPERIMENTAL NEOPLASM; FIBROSARCOMA; FINITE ELEMENT ANALYSIS; HUMAN; MOLECULAR LIBRARY; NUDE MOUSE; PATHOLOGY; PHARMACOLOGY; PROCEDURES; SINGLE CELL ANALYSIS; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; CELL LINE, TUMOR; ENZYME INHIBITORS; FIBROSARCOMA; FINITE ELEMENT ANALYSIS; HUMANS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PHTHALAZINES; PIPERAZINES; SINGLE-CELL ANALYSIS; SMALL MOLECULE LIBRARIES; SUBCELLULAR FRACTIONS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921310630     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0801     Document Type: Article

References (64)

1. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6:583-92.
2. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 2008;60:1421-34.
3. Thurber GM, Weissleder R. A systems approach for tumor pharmacokinetics. PLoS ONE 2011;6:e24696.
4. Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1999;01:241-63.
5. Patel KJ, Tannock IF. The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors. BMC Cancer 2009;9.
6. Kyle AH, Huxham LA, Yeoman DM, Minchinton AI. Limited tissue penetration of taxanes: A mechanism for resistance in solid tumors. Clin Cancer Res 2007;13:2804-10.
7. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011;91:1071-121.
8. Thurber GM, Weissleder R. Quantitating antibody uptake in vivo: conditional dependence on antigen expression levels. Mol Imaging Biol 2011;13:623-32.
9. Su H, Seimbille Y, Ferl GZ, Bodenstein C, Fueger B, Kim KJ, et al. Evaluation of [F-18]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging 2008;;35:1089-99.
10. Tolmachev V, Stone-Elander S, Orlova A. Radiolabelled receptortyrosine- kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol 2010;11:992-1000.
11. Doubrovin M, Kochetkova T, Santos E, Veach DR, Smith-Jones P, Pillarsetty N, et al. I-124-Iodopyridopyrimidinone for PET of Abl kinaseexpressing tumors in vivo. J Nucl Med 2010;51:121-9.
12. Pries AR, Cornelissen AJM, Sloot AA, Hinkeldey M, Dreher MR, Hopfner M, et al. Structural adaptation and heterogeneity of normal and tumor microvascular networks. PLoS Comput Biol 2009;5:11.
13. Dewhirst MW, Klitzman B, Braun RD, Brizel DM, Haroon ZA, Secomb TW. Review of methods used to study oxygen transport at the microcirculatory level. Int J Cancer 2000;90:237-55.
14. Schroeder T, Yuan H, Viglianti BL, Peltz C, Asopa S, Vujaskovic Z, et al. Spatial heterogeneity and oxygen dependence of glucose consumption in R3230Ac and fibrosarcomas of the Fischer 344 rat. Cancer Res 2005;65:5163-71.
15. Helmlinger G, Sckell A, Dellian M, Forbes N, Jain RK. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res 2002;8:1284-91.
16. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557-U4.
17. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
18. Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 2009;459:428-U144.
19. De Souza R, Zahedi P, Badame RM, Allen C, Piquette-Miller M. Chemotherapy dosing schedule influences drug resistance development in ovarian cancer. Mol Cancer Ther 2011;10:1289-99.
20. Ramachandran C, Sauerteig A, Sridhar KS, Thurer RJ, Krishan A. MDR-1 gene-expression, anthracycline retention and cytotoxicity in human lung-tumor cells from refractory patients. Cancer Chemother Pharmacol 1993;31:431-41.
21. Kim BJ, Forbes NS. Single-cell analysis demonstrates how nutrient deprivation creates apoptotic and quiescent cell populations in tumor cylindroids. Biotechnol Bioeng 2008;101:797-810.
22. McKillop D, Partridge EA, Kemp JV, SpenceMP, Kendrew J, Barnett S, et al. Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol Cancer Ther 2005;4:641-9.
23. Kuh HJ, Jang SH, Wientjes MG, Weaver JR, Au JLS. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther 1999;290:871-80.
24. Lesser GJ, Grossman SA, Eller S, Rowinsky EK. The distribution of systemically administered [H-3] paclitaxel in rats - A quantitative autoradiographic study. Cancer Chemother Pharmacol 1995;37:173-8.
25. Gangloff A, Hsueh WA, Kesner AL, Kiesewetter DO, Pio BS, Pegram MD, et al. Estimation of paclitaxel biodistribution and uptake in humanderived xenografts in vivo with F-18-fluoropaclitaxel. J Nucl Med 2005;46:1866-71.
26. Tannock I, Lee C, Tunggal J, Cowan D, Egorin M. Limited penetration of anticancer drugs through tumor tissue: A potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002;8:878-84.
27. Minchinton AI, Wendt KR, Clow KA, Fryer KH. Multilayers of cells growing on a permeable support. An in vitro tumour model. Acta Oncol 1997;36:13-6.
28. Pruijn FB, Sturman JR, Liyanage HDS, Hicks KO, Hay MP, Wilson WR. Extravascular transport of drugs in tumor tissue: Effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures. J Med Chem 2005;48:1079-87.
29. Sutherland R. Cell and environment interactions in tumor microregions: The multicell spheroid model. Science 1988;240:177-84.
30. Toley BJ, Tropeano Lovatt ZG, Harrington JL, Forbes NS. Microfluidic technique to measure intratumoral transport and calculate drug efficacy shows that binding is essential for doxorubicin and release hampers Doxil. Integr Biol 2013;5:1184.
31. Sung C, Youle RJ, Dedrick RL. Pharmacokinetic analysis of immunotoxin uptake in solid tumors - role of plasma kinetics, capillary-permeability, and binding. Cancer Res 1990;50:7382-92.
32. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009;8:2861.
33. El-Kareh AW, Secomb TW. Theoretical models for drug delivery to solid tumors. Crit Rev Biomed Eng 1997;25:503-71.
34. Baxter L, Zhu H, Mackensen D, Jain RK. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor Xenografts in nude mice. Cancer Res 1994;54:1517-28.
35. Venkatasubramanian R, Arenas RB, Henson MA, Forbes NS. Mechanisticmodelling of dynamicMRI data predicts that tumour heterogeneity decreases therapeutic response. Br J Cancer 2010;103:486-97.
36. Beerling E, Ritsma L, Vrisekoop N, Derksen PWB, van Rheenen J. Intravital microscopy:new insights into metastasis of tumors. J Cell Sci 2011;124:299-310.
37. Bravo-Cordero JJ, Hodgson L, Condeelis J. Directed cell invasion and migration during metastasis. Current Opinion in Cell Biology. 2012;24:277-83.
38. Wyckoff J, Gligorijevic B, Entenberg D, Segall J, Condeelis J. Highresolution multiphoton imaging of tumors in vivo. Cold Spring Harb Protocols. 2011;2011:1167-84.
39. Yang KS, Budin G, Reiner T, Vinegoni C, Weissleder R. Bioorthogonal imaging of aurora kinase a in live cells. Angew Chem Int Ed 2012;51:6598-603.
40. Thurber GM, Yang KS, Reiner T, Kohler RH, Sorger P, Mitchison T, et al. Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. Nat Commun 2013;4:1504.
41. Reiner T, Lacy J, Keliher EJ, Yang KS, Ullal A, Kohler RH, et al. Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents. Neoplasia 2012;14:169-77.
42. Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, et al. 4-3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl -2H-ph thalazin-1-one: A novel bioavailable inhibitor of poly (ADP-ribose) polymerase-1. J Med Chem 2008;51:6581-91.
43. Gerlowski L, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc Res 1986;31:288-305.
44. Crank J. The mathematics of diffusion. 2 ed. Oxford, UK: Clarendon Press; 1975.
45. Rosania GR, Lee JW, Ding L, Yoon HS, Chang YT. Combinatorial approach to organelle-targeted fluorescent library based on the styryl scaffold. J Am Chem Soc 2003;125:1130-1.
46. Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 2002;91:129-56.
47. Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. In: Cho AK, editor. Annual review of pharmacology and toxicology. Palo Alto, CA: Annual Reviews; 2011. p. 45-73.
48. Praxmarer M, Sung C, Bungay PM, van Osdol WW. Computational models of antibody-based tumor imaging and treatment protocols. Ann Biom Eng 2001;29:340-58.
49. Choi HS, Liu W, Liu F, Nasr K, Misra P, Bawendi MG, et al. Design considerations for tumour-targeted nanoparticles. Nat Nanotechnol 2010;5:42-7.
50. Lee H, Hoang B, Fonge H, Reilly RM, Allen C. In vivo distribution of polymeric nanoparticles at the whole-body, tumor, and cellular levels. Pharm Res 2010;27:2343-55.
51. Dreher MR, Liu WG, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 2006;98:335-44.
52. Wu NZ, Klitzman B, Rosner G, Needham D, Dewhirst MW. Measurement of material extravasation in microvascular networks using fluorescence video-microscopy. Microvasc Res 1993;46:231-53.
53. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl) ation reactions in the regulation of nuclear functions. Biochem J 1999;342:249-68.
54. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25.
55. Taskinen J, Yliruusi J. Prediction of physicochemical properties based on neural network modelling. Adv Drug Deliv Rev 2003;55:1163-83.
56. Mager DE. Quantitative structure-pharmacokinetic/pharmacodynamic relationships. Adv Drug Deliv Rev 2006;58:1326-56.
57. Rixe O, Franco SX, Yardley DA, Johnston SR, Martin M, Arun BK, et al. A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patientswith pretreated metastatic breast cancer. Cancer Chemother Pharm 2009;64:1139-48.
58. Ramalingam SS, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2012;30:3337-44.
59. Janne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, et al. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 2011;17:1131-9.
60. Yeh HH, Ogawa K, Balatoni J, Mukhapadhyay U, Pal A, Gonzalez- Lepera C, et al. Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proc Natl Acad Sci US A 2011;108:1603-8.
61. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008;49:129S-48S.
62. Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD, et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004;305:1466-70.
63. Monnich D, Troost EGC, Kaanders J, Oyen WJG, Alber M, Thorwarth D. Modelling and simulation of (18)F fluoromisonidazole dynamics based on histology-derived microvessel maps. Phys Med Bio 2011;56:2045-57.
64. Mullani NA, Herbst RS, O'Neil RG, Gould KL, Barron BJ, Abbruzzese JL. Tumor blood flow measured by PET dynamic imaging of first-pass F-18-FDG uptake: a comparison with O-15-Labeled water-measured blood flow. J Nucl Med 2008;49:517-23.